Silver Place/iStock via Getty Images
- Viatris (VTRS) said that top-line phase 3 results for Nefecon (targeted-release budesonide) in primary immunoglobulin A nephropathy (IgAN) met primary and secondary endpoints in a Japanese trial.
- In the open-label study, patients on Nefecon, also called VR-205, saw a 33.75% decline